Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00333151 · ClinicalTrials.gov registry record · Phase 3
Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 576
- Enrollment target
NCT00333151 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 576 participants.
The verdict
NCT00333151, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 576 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.
Interventions
- DRUG metformin
- DRUG liraglutide
- DRUG rosiglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 576 participants |
| Start Date | 2006-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00333151
The ClinicalTrials.gov registry entry for NCT00333151 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 576 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which metformin is the first listed.
NCT00333151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00333151 about?
NCT00333151 is a clinical study titled "Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes". This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alon...
What is the current status of trial NCT00333151?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 576 participants. The study started on 2006-05. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00333151?
The interventions under investigation include: metformin (DRUG), liraglutide (DRUG), rosiglitazone (DRUG).
Who is sponsoring clinical trial NCT00333151?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.